However, IVIG distributes throughout the intravascular and extravascular fluid compartments of the body with minimal distribution into lipophilic material. 5 Siegel 6 reported that evidence suggests that it is more appropriate to determine the dose of IVIG for an obese patient using adjusted BW or IBW as opposed to actual BW. In 2007, the United Kingdom's Department of Health issued clinical guidance documents that recommended IVIG dosing by adjusted BW. 7 The department retracted that recommendation in 2011, citing a lack of evidence, and suggested that prescribers merely consider adPurpose. Correlations between the i.v. immune globulin (IVIG) dose and the change in serum immunoglobulin G (IgG) concentration with three methods of weightbased dosing were investigated. Methods. A retrospective medical records review was conducted to identify patients in a multicenter healthcare system who received IVIG over a 10-year period and had serum IgG measurements within two days before and two days after the date of IVIG administration. For each of the 11 adults and 7 adolescents identified, the relationship between the weight-based dose of IVIG (determined using actual body weight [ 
Conclusion.
In adult patients, the correlation between the dose of IVIG and the change in IgG level was strongest when doses were calculated using IBW; comparable degrees of correlation were observed with the three evaluated methods of weightbased dosing in the adolescent population. Am J Health-Syst Pharm. 2015; 72:285-9 justed BW for dosing IVIG in obese patients. 8 The purpose of the study described here was to explore correlations between IVIG dosages based on IBW, actual BW, or adjusted BW with the increase in serum immunoglobulin G (IgG) levels after IVIG administration.
Methods
Data collection. We performed a retrospective study of patients receiving IVIG at any facility within our health system from January 2003 through December 2012. The study was approved and granted a waiver of informed consent by the health system's institutional review board. Patients were identified using the system's electronic database. Patient cases were included in the study if two serum IgG levels were obtained: the first, up to two calendar days preceding IVIG administration; and the second, up to two calendar days after the date of IVIG administration. Patients were included only once in the study.
The cumulative IVIG dose was used for patients who received two doses of IVIG between the predose and postdose serum IgG determinations. If a patient did not have a singledose IVIG administration with corresponding IgG levels, data from the chronologically first multipledose administration of IVIG were utilized.
The following data were collected for the analysis: patient height, weight, and sex; IVIG dose and administration date; and serum IgG concentrations and acquisition dates. The change in serum IgG level was defined as the IgG level after treatment minus the IgG level before treatment.
The following equations were used to calculate IBW and adjusted BW: Statistical analysis. For each patient, each weight-based dose of administered IVIG (i.e., the dose divided by actual BW, adjusted BW, or IBW) was evaluated in relation to the corresponding change in serum IgG level. Simple regression analysis was performed using the online statistical application VassarStats (Lowry R, Vassar College, Poughkeepsie, NY). Lines of regression and Pearson correlation coefficients (r values), with corresponding two-sided p values, were calculated. Secondarily, the Fisher r-to-z transformation was performed to assess differences between correlation coefficients. The a priori level of significance was set at 0.05.
Results
Eleven adult patients and 7 adolescent patients (12-17 years of age) met the inclusion criteria. Patient demographic information is provided in Table 1 . In the adolescent patient population, 3 of the 7 patients had an actual BW greater than or equal to 120% of their IBW. The adolescents' weights ranged from 88% to The analysis of data on changes in serum IgG concentrations that resulted from IVIG dose determinations based on IBW, adjusted BW, and actual BW in adolescent patients (Figure 2 ) yielded correlation coefficients of 0.99 (p < 0.0005), 0.99 (p < 0.0005), and 0.95 (p < 0.005), respectively. There were no significant differences in r values for IBWbased dosing and for dosing based on either adjusted BW or actual BW.
Demographics and I.V. Immune Globulin (IVIG) Dosing
Adults (n = 11) Female Male Mean ± S.D. age (yr) Mean ± S.D. height (cm) Mean ± S.D. weight (kg) Mean ± S.D. IVIG dose (g/kg) Adolescents (n = 7) Variable 4 7 50 ± 20 173 ± 9 81 ± 18 0.4 ± 0.2 4 3 15 ± 1 163 ± 3 61 ± 11 0.6 ± 0.3
Discussion
In this study, we evaluated the 
Dose (g)/IBW (kg)
0 correlation of IVIG dose determinations based on IBW, adjusted BW, and actual BW to postdose changes in serum IgG levels. The strongest correlation was observed with IBWbased dosing; however, the differences in the calculated r values for that dosing method and for dosing based on actual or adjusted BW were not statistically significant. To our knowledge, this is the first study to demonstrate correlations between IVIG weight-based doses and serum IgG levels in this manner. A retrospective study published in 2011 evaluated the relationships of IgG trough level to annual IVIG dose, annual weight-based IVIG dose, and body mass index (BMI)-based annual IVIG dose. 10 The study authors concluded that doses adjusted for BW or BMI did not correlate with postdose serum IgG trough levels and that dosing by IBW instead would preserve IVIG resources and also reduce the cost of therapy without affecting trough level attainment. Additionally, a study of IVIG pharmacokinetics in pregnant women reported peak and four-week serum IgG trough levels for women who received doses of 0.5-1.0 g/kg.
11 During the first and second trimesters of pregnancy, the mean trough levels in the 1.0-and 0.5-g/kg dosing groups were not different. In contrast, the mean IgG peak level for patients who received 1.0 g/kg of IVIG was different from the mean peak level for those who received 0.5 g/kg of IVIG, suggesting that the correlation between IVIG dosing and IgG levels is more pronounced for peak versus trough values. Also, a recently published prospective study of serum IgG levels in patients treated with IVIG for chronic inflammatory demyelinating polyneuropathy demonstrated an association between the IVIG dose and the change in IgG level, with the authors reporting a correlation coefficient of 0.78 (p < 0.001). 12 Patients in the study received 20-75 g of IVIG per dose at varying infusion intervals over the course of the study. The authors did not find a correlation between weight and change in IgG levels. Data on weight-based doses and corresponding changes in IgG level were not reported.
Immunoglobulin undergoes concentration-dependent catabolism. It has been reported that the majority of the catabolism occurs using intravascular immunoglobulin supplies and is regulated through the neonatal Fc receptor for IgG. 13 Therefore, a larger dose of IVIG leading to higher intravascular IgG levels would result in higher rates of immunoglobulin catabolism initially. The theory of concentration-dependent catabolism offers an explanation for why, in previous studies, no correlation has been found between IgG trough levels and IVIG dosing but an association has been demonstrated between the IVIG dose and the change in serum IgG level. 10, 12 Our study now reports a correlation between the weight-based dose and the change in serum IgG level.
Use of IBW or adjusted BW for the dosing of IVIG is widely practiced. Given that IVIG has a relatively small volume of distribution, it has been proposed that IVIG has little accumulation in fat and tissue. Following this rationale, administering IVIG according to IBW or adjusted BW is theoretically appropriate in individuals whose actual BW exceeds their IBW. Considerations pertaining to cost of therapy and limited supply provide further motivation for institutions to adopt this adjustment in dosing. For example, Rocchio et al.
14 recently reported a 20% theoretical reduction in the amount of IVIG dispensed in a 12-month study period with implementation of IVIG dosing according to IBW for all indications at their institution (relative to the previously used actual BW-based dosing guideline). In our limited study, if IBW had been used for all adult patients with weights greater than their IBW, there would have been a 20% reduction in IVIG use. The 11 adult patients received a cumulative 373 g of IVIG; if IBW-based dosing had been implemented, they would have cumulatively received 298 g. The adolescent population of our study would have seen a 17% reduction in IVIG utilization with IBW-based dosing as opposed to dosing based on actual BW.
Limitations of our study included its retrospective nature and limited sample size. The timing of determinations of IgG peak and trough levels was inconsistent between individuals. Any patient who received IVIG and underwent IgG determinations within the specified time periods was included in the analysis regardless of diagnosis. Consideration was not given to the brand of IVIG administered. Certain diseases result in altered pharmacokinetic profiles for IVIG; this was not assessed during the analysis of the data. A review of patient records to determine outcomes was not included in this study. The patient data were strictly evaluated for IVIG doses given and IgG levels attained.
Conclusion
In adult patients, the correlation between the dose of IVIG and the change in IgG level was strongest when doses were calculated using IBW; comparable degrees of correlation were observed with the three evaluated methods of weight-based dosing in the adolescent population.
